Company intelligence / Profile preview

Cerebral

Walnut, California, United States

Ownership: Private
Development stage: Other

Overview

Cerebral operates a nationwide platform for online therapy and psychiatric medication management for anxiety, depression, insomnia, showing commercial success with funding of over $462M and more than $4.8B valuation. Few published clinical trial results; effectiveness largely inferred from adoption and common statistics (e.g., combined therapy/medication helps 80% of major depression cases)

Therapeutic areas: Psychiatry
Modalities: Non-pharmacological therapySmall molecule
Industry: Non-Academic Healthcare

Partnerships

None major disclosed with pharmaceutical or biotech firms; core operations centered on digital health/platform partnerships

Beyond the preview

Go deeper on Cerebral.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerebral.

Explore the full profile